Sihuan Pharmaceutical Holdings Group Past Earnings Performance
Past criteria checks 0/6
Sihuan Pharmaceutical Holdings Group has been growing earnings at an average annual rate of 13%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been declining at an average rate of 9.9% per year.
Key information
13.0%
Earnings growth rate
12.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | -9.9% |
| Return on equity | -4.1% |
| Net Margin | -2.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Revenue & Expenses Breakdown
How Sihuan Pharmaceutical Holdings Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,755 | -38 | 940 | 479 |
| 31 Mar 24 | 1,808 | -46 | 926 | 528 |
| 31 Dec 23 | 1,861 | -54 | 911 | 578 |
| 30 Jun 23 | 1,773 | -2,041 | 898 | 773 |
| 31 Mar 23 | 1,977 | -1,996 | 961 | 855 |
| 31 Dec 22 | 2,181 | -1,951 | 1,023 | 937 |
| 30 Jun 22 | 2,595 | -144 | 1,139 | 992 |
| 31 Mar 22 | 2,817 | 141 | 1,134 | 930 |
| 31 Dec 21 | 3,038 | 427 | 1,129 | 868 |
| 30 Sep 21 | 3,304 | 681 | 1,102 | 815 |
| 30 Jun 21 | 3,317 | 945 | 1,049 | 762 |
| 31 Mar 21 | 2,891 | 727 | 954 | 746 |
| 31 Dec 20 | 2,464 | 508 | 859 | 729 |
| 30 Sep 20 | 2,370 | -14 | 792 | 698 |
| 30 Jun 20 | 2,275 | -537 | 725 | 666 |
| 31 Mar 20 | 2,577 | -1,623 | 721 | 633 |
| 31 Dec 19 | 2,878 | -2,709 | 717 | 599 |
| 30 Sep 19 | 3,088 | -1,927 | 722 | 566 |
| 30 Jun 19 | 3,297 | -1,144 | 727 | 534 |
| 31 Mar 19 | 3,107 | 238 | 697 | 507 |
| 31 Dec 18 | 2,917 | 1,620 | 667 | 480 |
| 30 Sep 18 | 2,751 | 1,496 | 580 | 482 |
| 30 Jun 18 | 2,584 | 1,372 | 494 | 484 |
| 31 Mar 18 | 2,665 | 1,411 | 523 | 394 |
| 31 Dec 17 | 2,746 | 1,449 | 553 | 304 |
| 30 Sep 17 | 2,992 | 1,632 | 653 | 152 |
| 30 Jun 17 | 3,238 | 1,815 | 754 | 0 |
| 31 Mar 17 | 3,212 | 1,761 | 720 | 0 |
| 31 Dec 16 | 3,186 | 1,708 | 686 | 0 |
| 30 Sep 16 | 2,984 | 1,528 | 627 | 0 |
| 30 Jun 16 | 2,781 | 1,347 | 568 | 0 |
| 31 Mar 16 | 2,974 | 1,705 | 590 | 0 |
| 31 Dec 15 | 3,167 | 2,062 | 611 | 0 |
| 30 Sep 15 | 3,321 | 2,181 | 648 | 0 |
| 30 Jun 15 | 3,474 | 2,299 | 685 | 0 |
| 31 Mar 15 | 3,279 | 1,985 | 658 | 0 |
| 31 Dec 14 | 3,084 | 1,671 | 630 | 0 |
| 30 Sep 14 | 2,365 | 1,581 | 0 | 0 |
| 30 Jun 14 | 1,645 | 1,491 | -631 | 0 |
| 31 Mar 14 | 2,116 | 1,388 | -83 | 0 |
| 31 Dec 13 | 2,586 | 1,285 | 466 | 0 |
Quality Earnings: 460 is currently unprofitable.
Growing Profit Margin: 460 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 460 is unprofitable, but has reduced losses over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare 460's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 460 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Return on Equity
High ROE: 460 has a negative Return on Equity (-4.06%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 03:08 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Harry He | China Galaxy International Securities (Hong Kong) |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |